In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Medifast Inc (NYSE: MED) closed the day trading at $15.64 down -4.75% from the previous closing price of $16.42. In other words, the price has decreased by -$4.75 from its previous closing price. On the day, 0.35 million shares were traded. MED stock price reached its highest trading level at $16.1579 during the session, while it also had its lowest trading level at $15.45.
Ratios:
For a better understanding of MED, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.01 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.06. For the most recent quarter (mrq), Quick Ratio is recorded 2.55 and its Current Ratio is at 3.11. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.06.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, DA Davidson on November 05, 2024, Upgraded its rating to Neutral and sets its target price to $17 from $16.50 previously.
On June 05, 2024, DA Davidson Downgraded its rating to Underperform which previously was Neutral and also lowered its target price recommendation from $25 to $17.50.
On October 13, 2023, Stephens started tracking the stock assigning a Equal-Weight rating and target price of $82.Stephens initiated its Equal-Weight rating on October 13, 2023, with a $82 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 08 ’24 when SCHLACKMAN SCOTT sold 4,053 shares for $39.44 per share. The transaction valued at 159,866 led to the insider holds 7,785 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MED now has a Market Capitalization of 171067200 and an Enterprise Value of 14264621. As of this moment, Medifast’s Price-to-Earnings (P/E) ratio for their current fiscal year is 23.40, and their Forward P/E ratio for the next fiscal year is 52.13. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.17. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.25 while its Price-to-Book (P/B) ratio in mrq is 0.82. Its current Enterprise Value per Revenue stands at 0.021 whereas that against EBITDA is 0.528.
Stock Price History:
The Beta on a monthly basis for MED is 1.18, which has changed by -0.7462275 over the last 52 weeks, in comparison to a change of 0.23806548 over the same period for the S&P500. Over the past 52 weeks, MED has reached a high of $67.50, while it has fallen to a 52-week low of $16.40. The 50-Day Moving Average of the stock is -15.84%, while the 200-Day Moving Average is calculated to be -27.80%.
Shares Statistics:
Over the past 3-months, MED traded about 211.96K shares per day on average, while over the past 10 days, MED traded about 241770 shares per day. A total of 10.94M shares are outstanding, with a floating share count of 10.61M. Insiders hold about 2.96% of the company’s shares, while institutions hold 84.88% stake in the company. Shares short for MED as of 1734048000 were 1410856 with a Short Ratio of 6.66, compared to 1731628800 on 1596214. Therefore, it implies a Short% of Shares Outstanding of 1410856 and a Short% of Float of 19.600001.
Dividends & Splits
The stock’s 5-year Average Dividend Yield is 5.69.
Earnings Estimates
The firm’s stock currently is rated by 2.0 analysts. The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.06 and low estimates of -$0.32.
Analysts are recommending an EPS of between $1.83 and $1.71 for the fiscal current year, implying an average EPS of $1.77. EPS for the following year is $0.3, with 2.0 analysts recommending between $0.41 and $0.19.
Revenue Estimates
2 analysts predict $114.25M in revenue for the current quarter. It ranges from a high estimate of $119.6M to a low estimate of $108.9M. As of the current estimate, Medifast Inc’s year-ago sales were $191.01MFor the next quarter, 2 analysts are estimating revenue of $130.75M. There is a high estimate of $141.9M for the next quarter, whereas the lowest estimate is $119.6M.
A total of 2 analysts have provided revenue estimates for MED’s current fiscal year. The highest revenue estimate was $603.1M, while the lowest revenue estimate was $592.3M, resulting in an average revenue estimate of $597.7M. In the same quarter a year ago, actual revenue was $1.07BBased on 2 analysts’ estimates, the company’s revenue will be $509.85M in the next fiscal year. The high estimate is $541.1M and the low estimate is $478.6M.
